(Q40444417)

20 September 2017

Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling (English)

1 reference

20 September 2017

4

Matt van de Rijn

1 reference

20 September 2017

3

Shirley Zhu

1 reference

20 September 2017

1

C Blake Gilks

1 reference

20 September 2017

Barbara C Vanderhyden

series ordinal

2

1 reference

PubMed ID

15721412

20 September 2017

Teri A Longacre

series ordinal

5

1 reference

PubMed ID

15721412

20 September 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

20 September 2017

1 reference

20 September 2017

96

1 reference

20 September 2017

3

1 reference

20 September 2017

684-694

1 reference

Classification and Staging of Malignant Tumours in the Female Pelvis

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Microsatellite analysis in serous tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

A gene-expression signature as a predictor of survival in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Gene expression profiling predicts clinical outcome of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Diversity of gene expression in adenocarcinoma of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Molecular characterisation of soft tissue tumours: a gene expression study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Molecular portraits of human breast tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Gene expression patterns in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Cluster analysis and display of genome-wide expression patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Significance analysis of microarrays applied to the ionizing radiation response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Gene expression in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Expression of cell cycle regulators p57KIP2, cyclin D1, and cyclin E in epithelial ovarian tumors and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

DNA microarrays for assessing ovarian cancer gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Update on the role of topotecan in the treatment of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Molecular aspects of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.039

10.1016/J.YGYNO.2004.11.039

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference

PubMed ID

15721412